TEVA - Teva Pharmaceutical Industries Limited
| Previous Close | 8.20 |
| Open | 8.15 |
| Bid | 0.00 x 29200 |
| Ask | 0.00 x 1400 |
| Day's Range | 7.81 - 8.16 |
| 52 Week Range | 7.81 - 25.96 |
| Volume | 32,843,346 |
| Avg. Volume | 18,298,017 |
| Market Cap | 9.219B |
| Beta (3Y Monthly) | 2.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.42 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2017-11-27 |
| 1y Target Est | 13.95 |
- GlobeNewswire•5 hours ago
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BUD, EROS, PSMT, TEVA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
NEW ORLEANS, July 17, 2019 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending.
- Zacks•10 hours ago
Teva Pharmaceutical Industries Ltd. (TEVA) Dips More Than Broader Markets: What You Should Know
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.11 in the latest trading session, marking a -1.1% move from the prior day.
- ACCESSWIRE•17 hours ago
CLASS ACTION UPDATE for TEVA, FDX and RBGLY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / July 17, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
- ACCESSWIRE•18 hours ago
Class Action Update - ASNA, BUD & TEVA - Bronstein, Gewirtz & Grossman, LLC
NEW YORK, NY / ACCESSWIRE / July 17, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed againstthe following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.
- Motley Fool•21 hours ago
3 Drug Stocks With Unimaginably Low P/E Ratios
These drug developers are all valued at less than four times this year's projected earnings per share.
- MarketWatch•yesterday
Opioid makers dumped 76 billion pills onto U.S. market over 7 critical years, data shows
Newly released federal data shows how drugmakers and distributors increased shipments of opioid painkillers across the U.S. as the nation’s addiction crisis accelerated from 2006 to 2012.
- ACCESSWIRE•yesterday
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CLDR, TEVA and FRED
CEDARHURST, NY / ACCESSWIRE / July 16, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.
- GlobeNewswire•yesterday
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Pivotal Software, Eros International, Teva Pharmaceutical Industries, and Helius Medical Technologies and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Pivotal Software, Inc., Eros International Plc, Teva Pharmaceutical Industries Ltd, and Helius Medical Technologies, Inc. Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Class Period: Securities pursuant or traceable to Pivotal’s April 2018 initial public offering (“IPO”) and/or securities purchased or acquired between April 24, 2019 and June 4, 2019 (the “Class Period”).
- Zacks•2 days ago
Teva Shares Fall Further as Morgan Stanley Downgrades Rating
Shares of Teva (TEVA) are on a downtrend on the risk of high litigation costs related to opioid epidemic in the United States. Morgan Stanley downgrades its rating on Teva.
- Benzinga•2 days ago
Option Trader Makes Bullish Bet On Lannett Rebound
On Tuesday morning, Benzinga Pro subscribers received two options alerts related to Lannett. At 9:36 a.m., a trader bought 854 Lannett call options at a $7.50 strike price that expire on Sept. 20. At 9:42 a.m., likely the same trader bought another 752 Sept. 20 $7.50 Lannett call options at the ask price of 45.1 cents.
- ACCESSWIRE•2 days ago
CLASS ACTION UPDATE for EROS, TEVA and FRED: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / July 16, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
- Zacks•2 days ago
J&J (JNJ) Beats on Q2 Earnings, Ups 2019 Sales Growth View
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2019 and raises 2019 guidance for operational sales growth for the second time this year.
- GlobeNewswire•2 days ago
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Teva Pharmaceutical Industries Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Teva Pharmaceutical Industries Ltd. (“Teva” or “the Company”) (NYSE: TEVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
- GlobeNewswire•2 days ago
CLASS ACTION UPDATE for BUD, TEVA, EQT and INS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, July 16, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
- GlobeNewswire•2 days ago
SHAREHOLDER ALERT: CLAIMSFILER REMINDS BUD, EROS, TEVA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
NEW ORLEANS, July 15, 2019 -- ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:.
- InvestorPlace•3 days ago
Teva Pharmaceuticals News: Why TEVA Stock Is Sliding Today
Teva Pharmaceuticals (NYSE:TEVA) is having a Monday of nightmares as some of the company's products have led to lawsuits, which brought about a major analyst downgrade, causing TEVA stock to plummet early in the week.Source: Shutterstock The Israel-based pharma business with a global reach suffered today as the company's opioid-linked litigation has only started to kick off, with thousands of new lawsuits on the horizon. The harmful painkillers recently led to a judge giving the green light for an $85 million settlement in the state of Oklahoma, ensuring that the company will not promote opioids in the state.This is only the tip of the iceberg for Teva, which had a Monday that saw Morgan Stanley lower the stock's rating from an Equal Weight to an Underweight. The firm added that its price target on TEVA stock has now decreased from $16 per share to $6 per share.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMorgan Stanley analyst David Risinger noted that the pharmaceutical giant, as well as competitors such as Endo International PLC (NASDAQ:ENDP), are experiencing "underappreciated risks" coming from buying group pressure, which are now more negative than predicted.These include a rise in generic competition, as well as the aforementioned opioid-related suits. The note arrived soon after Argus Capital upped its rating on TEVA stock to a buy with a $12 price target on July 5, 2019.TEVA stock fell 7.5% by day's end, while ENDO stock slid 3.7%. More From InvestorPlace * 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond * 7 Dependable Dividend Stocks to Buy * 7 Retail Stocks to Buy for the Second Half of 2019 * 10 Stocks to Sell for an Economic Slowdown The post Teva Pharmaceuticals News: Why TEVA Stock Is Sliding Today appeared first on InvestorPlace.
- Motley Fool•3 days ago
Why Callon Petroleum, Teva Pharmaceutical Industries, and PG&E Slumped Today
The indexes didn't make major moves today, but these stocks did.
- Reuters•3 days ago
UPDATE 4-Opioid 'kingpin' J&J fueled epidemic, Oklahoma argues at trial's end
Lawyers for the state of Oklahoma on Monday compared Johnson & Johnson to a drug cartel leader as they sought to hold the drugmaker responsible for fueling the U.S. opioid epidemic in the first trial to result from lawsuits over the crisis. Lawyers for the state, including Attorney General Mike Hunter, told a judge in Norman, Oklahoma that J&J's "greed" led the drugmaker to carry out a years-long marketing effort that caused "utter confusion" about the addictive painkillers' risks. Brad Beckworth, a lawyer for the state, said J&J knew opioids were harmful, yet minimized the risk of addiction in their marketing, resulting in a surge in overdose deaths as doctors overprescribed the drugs and they flooded the state.
- Investopedia•3 days ago
Teva Relief Rally Loses Steam After Analyst Downgrade
Teva Pharmaceutical shares moved lower after Morgan Stanley downgraded the stock to Underweight with a price target of $6 per share.
- ACCESSWIRE•3 days ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ASNA, BUD and TEVA
NEW YORK, NY / ACCESSWIRE / July 15, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
- Benzinga•3 days ago
Morgan Stanley Downgrades Teva, Endo On Drug Pricing And Litigation Concerns
Pharmaceutical stocks have been under pressure for the past few trading days, but one Wall Street analyst said the worst is yet to come for a handful of specialty drugmakers. The Analyst Morgan Stanley ...
- ACCESSWIRE•3 days ago
Class Action Reminder - ASNA, BUD & TEVA - Bronstein, Gewirtz & Grossman, LLC
NEW YORK, NY / ACCESSWIRE / July 15, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed againstthe following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.
- Barrons.com•3 days ago
Teva and Endo Stock Are Falling Because Opioid Suits Aren’t Going Away
The two generic drugmakers were down Monday morning, with Teva getting the worse of it, after a Morgan Stanley analyst downgraded them both, citing the ongoing litigation over prescription opioid sales.
- Business Wire•3 days ago
Teva Announces FDA Approval of AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder, a combination therapy digital inhaler with built-in sensors that connects to a companion mobile application to provide information on inhaler use to people with asthma. AirDuo® Digihaler™ is indicated for the treatment of asthma in patients aged 12 years and older.
- Reuters•3 days ago
Oklahoma, J&J to wrap up first trial over opioid crisis
Oklahoma's attorney general is expected on Monday to urge a judge to find Johnson & Johnson responsible for flooding the market with painkillers and fueling the U.S. opioid epidemic, as the first trial in nationwide litigation over the drug crisis comes to an end. Lawyers for Attorney General Mike Hunter and J&J are set to deliver closing arguments in state court in Norman, Oklahoma following six weeks of testimony from current and former J&J executives and victims of the epidemic. The Oklahoma case is being closely watched by plaintiffs in other opioid lawsuits, particularly in 1,900 cases pending in Ohio brought largely by cities and counties against J&J and other companies.
